<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02259231</url>
  </required_header>
  <id_info>
    <org_study_id>RTA 408-C-1401</org_study_id>
    <nct_id>NCT02259231</nct_id>
  </id_info>
  <brief_title>RTA 408 Capsules in Patients With Melanoma - REVEAL</brief_title>
  <official_title>An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant melanoma is a leading cause of death from cutaneous malignancies, accounting for
      approximately three-fourths of all skin cancer deaths. For metastatic or unresectable
      melanomas, standard treatment options include immune checkpoint inhibitors (e.g., ipilimumab
      and nivolumab) and other therapies, however, approved therapies are rarely curative.

      It is now well accepted that tumors are able to evade detection and eradication by the immune
      system, even though many tumor types, particularly melanoma, are capable of eliciting a
      strong immune response (Swann, 2007). Substantial mechanistic work in recent years has
      revealed the key role of myeloid-derived suppressor cells (MDSCs) in masking cancer cells
      from the immune system, promoting both tumor progression and resistance to cancer
      immunotherapy. The immune-suppressive effect of MDSCs is dependent on the production of
      reactive oxygen species (ROS) and reactive nitrogen species (RNS). High levels of these
      reactive molecules and their by-products, such as nitrotyrosine, have been correlated with
      poor clinical outcomes in melanoma. Currently available melanoma therapies do not target
      MDSCs.

      In animals, RTA 408 significantly reduces tumor nitrotyrosine burden, inhibits the activity
      of MDSCs, and augments T-cell anticancer activity at relevant doses. Thus, through inhibition
      of MDSC activity and suppression of tumor ROS/RNS, RTA 408 may work in combination with
      T-cell-activating therapeutics such as ipilimumab to enhance the natural immune anticancer
      response. RTA 408 also has direct anticancer effects via inhibition of NF-kappa B. Chronic
      activation of NF-kappa B is associated with tumor progression, metastasis, and resistance to
      therapy.

      This proposed study is designed to assess the safety, efficacy, pharmacodynamics, and
      pharmacokinetics of omaveloxolone (RTA 408) in combination with ipilimumab or nivolumab in
      patients with unresectable or metastatic melanoma.

      In this open-label, multicenter, dose-escalation, Phase 1b/2 study, patients who qualify will
      receive omaveloxolone (RTA 408) at the assigned dose level in combination with ipilimumab or
      nivolumab. Patients will receive omaveloxolone (RTA 408) orally once daily for 1 week prior
      to initiation of ipilimumab or nivolumab. For patients treated with ipilimumab , the run-in
      period will be followed by omaveloxolone (RTA 408) orally once daily in combination with
      ipilimumab administered at Weeks 1, 4, 7, and 10. After Week 10, patients will receive
      maintenance treatment with omaveloxolone (RTA 408) alone once daily. For patients treated
      with nivolumab, the run-in period will be followed by omaveloxolone (RTA 408) orally once
      daily in combination with nivolumab administered approximately every two weeks as clinically
      indicated. Each patient will continue at the assigned omaveloxolone (RTA 408) dose level
      until disease progression occurs, toxicity requiring discontinuation from study drug (i.e.,
      RTA 408) is experienced, the patient has completed approximately 72 weeks of treatment, the
      patient is discontinued from the study drug for another reason, or the patient withdraws
      consent. Patients will return 4 weeks after omaveloxolone (RTA 408) treatment completion for
      a follow-up visit.

      The starting omaveloxolone (RTA 408) dose level for the first dose-escalation cohort in this
      study has been selected based on available safety and pharmacodynamic data from a Phase 1
      study of RTA 408 (NCT02029729). Subsequent cohorts will be enrolled at dose levels based on
      available safety and PD data from this study, but they will not be greater than 2-fold above
      the prior dose level.

      Phase 1b (dose-escalation): In the phase 1b/2 portion of this study, 12 patients will be
      enrolled in each dose cohort, with six patients administered omaveloxolone (RTA 408) plus
      ipilimumab and the remaining six administered rTA 408 plus nivolumab. Subsequent cohorts will
      assess escalating the doses of omaveloxolone (RTA 408) administered in combination with
      ipilimumab or nivolumab. Dose escalation decisions will be based on ongoing review of all
      available safety information for enrolled patients.

      Phase 2: The Phase 2 portion of the study may include separate expansion cohorts consisting
      of patients treated with either of the combination therapies. Each expansion cohort will
      include an additional 24 patients enrolled at the selected Phase 2 dose level to achieve a
      total of 30 patients at that omaveloxolone (RTA 408) dose in combination with ipilimumab or
      nivolumab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of overall response rate using RECIST (Response Evaluation Criteria in Solid Tumors) of the Phase 2 dose of omaveloxolone with nivolumab</measure>
    <time_frame>169 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Melanoma</condition>
  <condition>Unresectable (Stage III) Melanoma</condition>
  <condition>Metastatic (Stage IV) Melanoma</condition>
  <arm_group>
    <arm_group_label>Omaveloxolone 5 mg &amp; ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omaveloxolone (RTA 408) capsules, Dose1 taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone 10 mg &amp; ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone 5 mg &amp; nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omaveloxolone (RTA 408) capsules, 5 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone 10 mg &amp; nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone 20 mg &amp; nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omaveloxolone (RTA 408) capsules, 20 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone 100 mg &amp; nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omaveloxolone (RTA 408) capsules, 100 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone Dose5 TBD &amp; nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omaveloxolone (RTA 408) capsules, Dose5 TBD taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone Dose6 TBD &amp; nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omaveloxolone (RTA 408) capsules, Dose6 TBD taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone Capsules (2.5 mg/capsule)</intervention_name>
    <description>Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label</description>
    <arm_group_label>Omaveloxolone 5 mg &amp; ipilimumab</arm_group_label>
    <arm_group_label>Omaveloxolone 10 mg &amp; ipilimumab</arm_group_label>
    <arm_group_label>Omaveloxolone 5 mg &amp; nivolumab</arm_group_label>
    <arm_group_label>Omaveloxolone 10 mg &amp; nivolumab</arm_group_label>
    <arm_group_label>Omaveloxolone 20 mg &amp; nivolumab</arm_group_label>
    <arm_group_label>Omaveloxolone 100 mg &amp; nivolumab</arm_group_label>
    <arm_group_label>Omaveloxolone Dose5 TBD &amp; nivolumab</arm_group_label>
    <arm_group_label>Omaveloxolone Dose6 TBD &amp; nivolumab</arm_group_label>
    <other_name>RTA 408 Capsules (2.5 mg/capsule)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab (3 mg/kg)</intervention_name>
    <description>Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg</description>
    <arm_group_label>Omaveloxolone 5 mg &amp; ipilimumab</arm_group_label>
    <arm_group_label>Omaveloxolone 10 mg &amp; ipilimumab</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab (240 mg)</intervention_name>
    <description>Sterile solution containing nivolumab to be delivered intravenously at 240 mg</description>
    <arm_group_label>Omaveloxolone 5 mg &amp; nivolumab</arm_group_label>
    <arm_group_label>Omaveloxolone 10 mg &amp; nivolumab</arm_group_label>
    <arm_group_label>Omaveloxolone 20 mg &amp; nivolumab</arm_group_label>
    <arm_group_label>Omaveloxolone 100 mg &amp; nivolumab</arm_group_label>
    <arm_group_label>Omaveloxolone Dose5 TBD &amp; nivolumab</arm_group_label>
    <arm_group_label>Omaveloxolone Dose6 TBD &amp; nivolumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be ≥18 years of age;

          2. Have advanced, unresectable (Stage III) or metastatic (Stage IV) melanoma;

          3. Be eligible for commercial receipt of therapy to be used in this study in combination
             with RTA 408 (i.e., ipilimumab or nivolumab in the Phase 1b portion and nivolumab only
             in the Phase 2 portion);

          4. Have discontinued previous treatments for cancer;

          5. Have discontinued previous experimental therapies and checkpoint inhibitor antibodies
             at least 28 days prior to the Randomization Visit

        Exclusion Criteria:

          1. Have received prior treatment with therapy to be used in this study in combination
             with RTA 408 (i.e., ipilimumab or nivolumab) if enrolling in the Phase 2 portion of
             the study. This criterion does not apply to patients enrolling in the Phase 1b portion
             of the study.

          2. Have prior malignancy active within the previous 2 years;

          3. Have any active autoimmune disease or a history of known or suspected autoimmune
             disease;

          4. History of brain metastases that meet certain conditions;

          5. History of specific cardiovascular abnormalities;

          6. Have known active fungal, bacterial, and/or viral infection, including human
             immunodeficiency virus (HIV) or hepatitis virus (A,B, or C).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Southern Cancer Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>251-607-5283</phone>
    </contact>
    <investigator>
      <last_name>Michael Meshad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>479-587-1700</phone>
    </contact>
    <investigator>
      <last_name>Thaddeus J Beck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center, Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>720-848-7135</phone>
    </contact>
    <investigator>
      <last_name>Rene Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christiana Hospital Helen F. Graham Cancer Center</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>303-623-4639</phone>
    </contact>
    <investigator>
      <last_name>Michael Guarino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Goergetown-Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>202-687-2680</phone>
    </contact>
    <investigator>
      <last_name>Geoffrey Gibney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>813-745-4798</phone>
    </contact>
    <investigator>
      <last_name>Joseph Markowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>617-632-5906</phone>
    </contact>
    <investigator>
      <last_name>Frank Hodi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlantic Melanoma Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>973-971-5569</phone>
    </contact>
    <investigator>
      <last_name>Eric Whitman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>919-684-8239</phone>
    </contact>
    <investigator>
      <last_name>April Salama, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>713-792-2921</phone>
    </contact>
    <investigator>
      <last_name>Sapna Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2014</study_first_submitted>
  <study_first_submitted_qc>October 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2014</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RTA 408</keyword>
  <keyword>RTA 408 Capsules</keyword>
  <keyword>Myeloid-derived suppressor cells (MDSDs)</keyword>
  <keyword>iNOS</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Checkpoint inhibitor</keyword>
  <keyword>omaveloxolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

